Essity AB ESSITY B
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Keep the core position but reassess the case: monitor Cevian’s agenda/communications and management’s response, plus evidence that price/mix stabilises. Consider adding only if strategic steps become concrete or price/mix turns; reduce if margin pressure worsens without credible countermeasures.
Cevian as an active owner and the concrete tissue process represent major structural catalysts while new Sell recommendations and cost concerns warrant continued review.
Sentiment has turned more cautious after downgrades and concerns over margin pressure from higher input costs, despite support from buybacks and strategic reviews.
NEUTRAL is the call. Positive is the market mood. Low risk means less can go wrong.
Latest change
- 17 Sep 2026 — Sentiment trend shifts to declining driven by new Sell ratings from UBS and SB1 Markets together with margin pressure concerns from rising input costs.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (6) — follow the company freeAbout the company
Essity AB is a global producer of hygiene and health products with strong brands such as TENA and Tork. The company is mature and cash-flow generative, focusing on margin improvement through efficiency programs, buybacks, and selective acquisitions.
Bull case
Cevian as an active owner can drive portfolio changes and efficiencies that improve margins and capital allocation.
Bear case
Weak organic growth, price pressure and Sell recommendations increase the risk of lower margins if input costs continue to rise.
Why this signal
Cevian as an active owner and the concrete tissue process represent major structural catalysts while new Sell recommendations and cost concerns warrant continued review.
Recent news
Essity acquired Kenvue’s Brazilian feminine care business on 19 August for approximately SEK 2.7 billion. On 15 September reports emerged that the company is preparing a sale or listing process for the Consumer Tissue business at an indicated valuation of €2.5–3 billion, with the process expected to start in October. The buyback programme has continued and analysts from UBS and SB1 Markets have downgraded to Sell.